This month, the Genetics Journal Club features a double-blind randomized clinical trial which compared the use of a third-generation irreversible EGFR-TKI (osimertinib) versus standard therapy (gefitinib or erlotinib) to treat non small-cell lung cancer. You can read the results of this study in the New England Journal of Medicine.
Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., ... & Okamoto, I. (2017). Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine.
To learn more about EGFR mutations in non small-cell lung cancer, explore additional readings from Himmelfarb Library's full-text collection:
- Li, J & Bluth MH. (2017). Pharmacogenomics and Personalized Medicine. From Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. Elsevier, Inc.
- Shilpa J, Zhang DY, Xu R, Pincus MR & Lee, P. (2017). Molecular Genetic Pathology of Solid Tumors. From Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. Elsevier, Inc.
- Wagner, H. & Langer CJ. (2016). Non-Small Cell Lung Cancer. from Clinical Radiation Oncology. 4th ed. Elsevier, Inc.
Explore more of Himmelfarb Library's genetics collection by checking out:
